These results indicate that SMARCB1 not only functions as a tumor suppressor in lung cancer but also enhances tumor sensitivity to EGFR-TKI-afatinib treatment, in accordance with our in vivo lung cancer progression model (Fig. 3C, D). Here, SMARCB1 is linked to neoplasm.